1 / 34

Clostridium difficile

Clostridium difficile. Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC. Outline. Epidemiology Treatment Prevention. What is Clostridium difficile?. Anaerobic spore-forming bacillus Present in the soil and environment Produces two toxins – Toxins A and B

dashiell-marechal
Télécharger la présentation

Clostridium difficile

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clostridium difficile Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC

  2. Outline • Epidemiology • Treatment • Prevention

  3. What is Clostridium difficile? • Anaerobic spore-forming bacillus • Present in the soil and environment • Produces two toxins – Toxins A and B • Common cause of antibiotic associated diarrhea (AAD). 15 – 25 % all episodes of AAD • Health care settings are major reservoirs • 20 – 40% hospital patients colonized • 4 – 20% LTCF residents colonized

  4. What are C. difficile-associated diseases (CDAD) • Pseudomembranous colitis (PMC) • Toxic megacolon • Perforations of the colon • Sepsis • Death (rarely) but increasing!

  5. CDAD-related deaths - Arkansas *2005 data incomplete

  6. Symptoms of CDAD • Watery diarrhea • Fever • Loss of appetite • Abdominal pain • Nausea and vomiting • Severe cases: increase WBC and/or creatinine • Can occur up to 8 weeks after antimicrobial therapy

  7. Which patients are at increased risk for CDAD? • Antibiotic exposure – clindamycin, penicillins, cephalosporins, floroquinolones • Gastrointestinal surgery • Length of stay in healthcare settings • A serious underlying illness • Immunocompromising conditions • Advanced age

  8. C. difficile colonization • Patient exhibits no clinical symptoms • Patient tests positive for C. difficile organism and/or its toxin • More common than CDAD

  9. C. difficile disease (CDAD) • Patient exhibits clinical symptoms • Patient tests positive for C. difficile organism and/or its toxin

  10. Laboratory Tests for CDAD • Stool culture • Antigen detection • Toxin testing

  11. C. difficile Transmission • C. difficile spores are shed in feces • Any surface, device or material that becomes contaminated with feces may serve as a reservoir • Transferred by hands of healthcare personnel

  12. Treatment • Discontinue antibiotics if feasible • Metronidazole orally for 10 days • Vancomycin orally • Relapses are common • Repeat testing NOT recommended • NO antiperistalic agents

  13. Infection Control Preventive Methods • Use antibiotics judiciously • Early diagnosis • Contact precautions for patients with CDAD • Hand hygiene • Environmental cleaning and disinfection

  14. Contact Precautions • Private room or cohort • Gloves • Gowns • Dedicated patient care equipment

  15. Hand Hygiene Soap and water for at least 15 seconds: • Wet hands under running water • Apply soap • Good friction rub for 15 seconds • Rinse hands • Dry well with paper towel

  16. Cleaning and Disinfection • Clean/disinfect environmental surfaces and reusable items • Hospital disinfectant • 1:10 bleach

  17. Discontinuing Precautions • NO diarrhea. NO precautions! • Repeat testing NOT recommended

  18. Transfer of Patients • Notify receiving facility if patient has a history of C. difficile • Observe for recurrence

  19. References • SHEA Position Paper CDAD, ICHE 1995 • SHEA Position Paper C. difficile in LTCF for the elderly, ICHE 2002

  20. QUESTIONS?

More Related